Abstract

BACKGROUNDHispanics/Latinos are the fastest growing racial/ethnic groups in the United States,1 and account for 18% of the US population (representing 62.1 million people).2 However, Latinos account for only 2% of participants in clinical trials on Alzheimer's disease and related dementias (ADRD),3 as well as studies on ADRD funded by the National Institutes of Health.4 Manly and Glymour5 raised concerns about the recently US Food and Drug Administration–approved aducanamab, a drug to treat Alzheimer's disease (AD), as only 3% of participants in its trials identified as Latino. This underrepresentation is a concern considering projections that the number of Latinos with AD will increase 9‐fold by 2060, a growth of 832%.6 Emerging evidence also suggests that Latinos are at increased risk for developing ADRD. For example, two studies found that Caribbean Latinos in Northern Manhattan were twice as likely as non‐Latino Whites to have ADRD.7,8 The Alzheimer's Association estimated that Latinos are 1.5 times more likely than non‐Latino Whites using from data from the Health & Retirement Study.9 However, two other studies do not suggest higher ADRD incidence among Latinos versus non‐Latino Whites in Northern California.10,11The underrepresentation of Latinos in clinical trials on ADRD reduces the generalizability of research findings because